Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baras

Showing results (341-350 of 499) with videos related to

Pageof 50
Sort By:
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
Implications of the tumor immune microenvironment for staging and therapeuticsJanis M Taube, Jérôme Galon, Lynette M Sholl, et al.
Critical Care Medicine|July 16, 2019
Agreement With Consensus Statements on End-of-Life Care: A Description of Variability at the Level of the Provider, Hospital, and CountryAnn C Long, Lyndia C Brumback, J Randall Curtis, et al.
Vaccine|January 18, 2011
Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferretsBenoît Baras, Koert J Stittelaar, Thijs Kuiken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2017
Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder CancerMax Kates, Abhijit Date, Takahiro Yoshida, et al.
Ugeskrift for Laeger|May 13, 2005
[End-of-life practices in European intensive care units]Hans Henrik Bülow, Anne Lippert, Charles Sprung, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
European Urology Oncology|August 15, 2019
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder CancerMax Kates, Thomas R Nirschl, Alex S Baras, et al.
Diabetes|April 22, 2017
Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order AmishHuichun Xu, Kathleen A Ryan, Thomas J Jaworek, et al.
The Journal of Urology|November 25, 2015
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder CancerJong Chul Park, Nilay M Gandhi, Michael A Carducci, et al.
Plos One|January 3, 2008
Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccineBenoît Baras, Koert J Stittelaar, James H Simon, et al.
Pageof 50

Showing results (341-350 of 499) with videos related to

Sort By:
Pageof 50
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 2, 2017
Implications of the tumor immune microenvironment for staging and therapeuticsJanis M Taube, Jérôme Galon, Lynette M Sholl, et al.
Critical Care Medicine|July 16, 2019
Agreement With Consensus Statements on End-of-Life Care: A Description of Variability at the Level of the Provider, Hospital, and CountryAnn C Long, Lyndia C Brumback, J Randall Curtis, et al.
Vaccine|January 18, 2011
Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferretsBenoît Baras, Koert J Stittelaar, Thijs Kuiken, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2017
Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder CancerMax Kates, Abhijit Date, Takahiro Yoshida, et al.
Ugeskrift for Laeger|May 13, 2005
[End-of-life practices in European intensive care units]Hans Henrik Bülow, Anne Lippert, Charles Sprung, et al.
Annals of Nuclear Medicine|October 26, 2017
Low levels of PSMA expression limit the utility of <sup>18</sup>F-DCFPyL PET/CT for imaging urothelial carcinomaScott P Campbell, Alexander S Baras, Mark W Ball, et al.
European Urology Oncology|August 15, 2019
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder CancerMax Kates, Thomas R Nirschl, Alex S Baras, et al.
Diabetes|April 22, 2017
Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order AmishHuichun Xu, Kathleen A Ryan, Thomas J Jaworek, et al.
The Journal of Urology|November 25, 2015
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder CancerJong Chul Park, Nilay M Gandhi, Michael A Carducci, et al.
Plos One|January 3, 2008
Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccineBenoît Baras, Koert J Stittelaar, James H Simon, et al.
Pageof 50